Industry

OAKLAND, Calif.–(BUSINESS WIRE)–#COVID19–After surging during the height of the COVID-19 pandemic, the number of nonfatal work injuries and illnesses in California returned to pre-pandemic levels in 2024 according to a California Workers’ Compensation Institute (CWCI) review of data from the California Department of Industrial Relations (DIR) Director’s Office of Research. Recent results from California’s Survey … [Read more…]

Veteran nurse and healthcare executive brings heart-centered leadership, and operational excellence to advance the lifesaving work of LifeLink ATLANTA–(BUSINESS WIRE)–#donor—LifeLink Foundation today announced that Kelly Cullen, RN, MBA, has joined the organization as Chief Operating Officer (COO) to support the mission and continued growth of LifeLink. Cullen will provide strategic and operational leadership to advance … [Read more…]

Planned funding cuts by the provincial government will lengthen wait-times and worsen patient care in hospitals, warns CUPE OTTAWA–(BUSINESS WIRE)–As hospitals cut hundreds of jobs and eliminate vacant positions amidst budgetary constraints imposed by the Conservative government, the largest health care union in Ontario is warning about longer wait-times, rushed care, preventable mistakes, and overcrowded … [Read more…]

WILMINGTON, Del.–(BUSINESS WIRE)–Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines: Symbicort (budesonide/formoterol fumarate or BFF, a standard … [Read more…]

WALNUT CREEK, Calif.–(BUSINESS WIRE)–Paradigm (“Paradigm” or the “Company”), a specialty care management organization focused on delivering solutions that improve outcomes for individuals with complex injuries and diagnoses, today announced that it has entered into a definitive agreement to be acquired by Patient Square Capital (“Patient Square”), a leading health care investment firm. This planned investment … [Read more…]

CHICAGO–(BUSINESS WIRE)–The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading … [Read more…]

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / … [Read more…]

CompHealth, Weatherby Healthcare, and Global Medical Staffing earn top satisfaction scores, demonstrating CHG Healthcare’s industry‑leading commitment to provider experience and service excellence. MIDVALE, Utah–(BUSINESS WIRE)–CHG Healthcare, the nation’s largest physician staffing firm and industry leader in healthcare workforce success, announced today that three of its staffing brands — CompHealth, Weatherby Healthcare, and Global Medical Staffing … [Read more…]

Expert-led live sessions to run during Eating Disorders Awareness Week ST. PAUL, Minn.–(BUSINESS WIRE)–The Emily Program, a national leader in eating disorder specialty care and behavioral health services, today announced its 2026 Learn with Emily webinar series. Designed for advocates, caregivers, and clinicians, the free, expert-led series explores insights on eating disorder care and recovery. … [Read more…]

BOSTON–(BUSINESS WIRE)–#activitiesofdailyliving—Encora Therapeutics, a leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Encora X1™. This clearance is supported by data from two clinical studies: a randomized, sham-controlled trial and a 90-day home-use study. Together, these studies demonstrated consistent improvements in tremor severity … [Read more…]